Germline Multigene Panel Testing in Women With Invasive Lobular Cancer - Takeaways - MDSpire

Germline Multigene Panel Testing in Women With Invasive Lobular Cancer

  • By

  • Giovanni Corso

  • Elena Marino

  • Francesca Fava

  • Fabrizio Natali

  • Paolo Peterlongo

  • Matteo Dal Molin

  • Irene Feroce

  • Cristina Zanzottera

  • Giulia Massari

  • Susanna Di Silvestre

  • Micol Moscatiello

  • Andrea Franceschini

  • Vincenzo Bagnardi

  • Giuseppe Curigliano

  • Bernardo Bonanni

  • Paolo Veronesi

  • Francesco Bertolini

  • July 8, 2026

  • 0 min

Share

  • 1

    Invasive lobular carcinoma (ILC) accounts for 10% to 15% of breast cancer cases and is characterized by a diffuse growth pattern and reduced cell cohesion.

  • 2

    Germline pathogenic variants in genes like CDH1 and BRCA2 are strongly associated with increased ILC risk, particularly in women diagnosed before age 40.

  • 3

    The study aims to evaluate outcomes of germline variants in a large cohort of women with primary ILC undergoing multigene panel testing.

  • 4

    A total of 113 genes were analyzed in the study, with blood samples collected from women diagnosed with ILC between May 2022 and January 2025.

  • 5

    Patients were classified based on germline variant status into carriers of moderate- to high-risk variants and noncarriers of such variants.

Original Source(s)

Germline Multigene Panel Testing in Women With Invasive Lobular Cancer

  • by Giovanni Corso, Elena Marino, Francesca Fava, Fabrizio Natali, Paolo Peterlongo, Matteo Dal Molin, Irene Feroce, Cristina Zanzottera, Giulia Massari, Susanna Di Silvestre, Micol Moscatiello, Andrea Franceschini, Vincenzo Bagnardi, Giuseppe Curigliano, Bernardo Bonanni, Paolo Veronesi, Francesco Bertolini

  • July 8, 2026

Related Content

Multimodal imaging features of primary breast epithelial–myoepithelial carcinoma: a case report and literature review

Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications

Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study